KFS
ALNY icon

Kurt F. Somerville’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kurt F. Somerville’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-9,020
Closed -$460K – 106
2017
Q1 		$460K Sell
9,020
-6,117
-40% -$283K 0.1% 78
2016
Q4 		$565K Buy
15,137
+5
+0% +$209 0.13% 75
2016
Q3 		$1.02M Hold
15,132
– – 0.22% 62
2016
Q2 		$840K Buy
15,132
+2
+0% +$126 0.19% 62
2016
Q1 		$949K Sell
15,130
-80
-0.5% -$5.32K 0.22% 61
2015
Q4 		$1.43M Buy
15,210
+2,293
+18% +$213K 0.33% 55
2015
Q3 		$1.04M Sell
12,917
-310
-2% -$34.4K 0.26% 58
2015
Q2 		$1.58M Sell
13,227
-160
-1% -$19.1K 0.37% 51
2015
Q1 		$1.4M Buy
13,387
+105
+0.8% +$10.6K 0.32% 56
2014
Q4 		$1.29M Buy
13,282
+6,965
+110% +$645K 0.32% 56
2014
Q3 		$493K Hold
6,317
– – 0.2% 71
2014
Q2 		$400K Sell
6,317
-475
-7% -$28.2K 0.16% 81
2014
Q1 		$456K Sell
6,792
-6,693
-50% -$518K 0.18% 77
2013
Q4 		$867K Sell
13,485
-738
-5% -$44K 0.33% 57
2013
Q3 		$910K Hold
14,223
– – 0.36% 57
2013
Q2 		$440K Buy
+14,223
New +$378K 0.18% 77

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Kurt F. Somerville's ALNY Position: Q2 2017 in Review

Kurt F. Somerville sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2017, closing a stake of 9,020 shares — an estimated $460K sold.

Kurt F. Somerville first reported a position in ALNY in Q2 2013 and held it in 16 quarters. The position peaked at $1.58M in Q2 2015. 227 funds tracked by Wall St. Rank hold ALNY as of Q2 2017.

  • Kurt F. Somerville reported no remaining Alnylam Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Kurt F. Somerville sold 9,020 Alnylam Pharmaceuticals shares in Q2 2017, an estimated $460K.
  • Kurt F. Somerville first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 16 quarters.
  • Kurt F. Somerville's Alnylam Pharmaceuticals position peaked at $1.58M in Q2 2015.
  • 227 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2017.

Based on Kurt F. Somerville's 13F filing for Q2 2017, filed 25 Jul 2017.